Skip to main content
HairCited

Minoxidil Figuras

23 figuras de investigación revisada por expertos

Todos Aceite de Romero Ácidos Grasos Omega-3 Cafeína (Tópica) Colágeno Dutasteride Finasteride Hierro L-Cysteine Microagujación Minoxidil MSM Queratina Selenio Spironolactone Terapia Láser de Baja Intensidad Terapia PRP Vitamina B12 Vitamina D Zinc
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 5
Figure 5

Oral low-dose minoxidil has emerged as an alternative to topical formulations for hair loss treatment, with studies suggesting systemic administration may benefit patients who experience scalp irritation from topical application. Cardiovascular monitoring is indicated for oral use.

Minoxidil and its use in hair disorders: a review.

Figure 1
Figure 1

Treatment options for androgenetic alopecia range from FDA-approved pharmacological agents (minoxidil and finasteride) to emerging therapies including low-level laser therapy, platelet-rich plasma, and hair transplantation. Efficacy, side effect profiles, and patient compliance vary substantially across modalities.

Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and …

Scheme 1.Scheme 1.CONSORT (Consolidated Standards of Reporting Trials) flow diagram.CONSORT (Consolidated Standards of Reporting Trials) flow diagram.
Figure 5 Flowchart

The CONSORT (Consolidated Standards of Reporting Trials) flow diagram documents the systematic review process from identification through screening, eligibility assessment, and final inclusion of studies evaluating PRP for androgenetic alopecia.

Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil®, …

Fig. 1. Clinical example of female pattern hair loss
Figure 3 Photograph

A clinical photograph demonstrating female pattern hair loss, showing characteristic diffuse thinning across the crown and mid-scalp. FPHL affects women with varying degrees of severity and may lead to significant psychological distress.

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.

Fig. 2. Ludwig scale representation
Figure 4 Diagram

The Ludwig scale classifies female pattern hair loss into three progressive stages, ranging from minimal thinning at the crown (Grade I) to extensive hair loss across the top of the scalp (Grade III). This grading system remains one of the most widely used clinical tools for assessing FPHL severity.

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.

Fig. 3. Sinclair Scale Sinclair’s classification. MPA is divided into four levels of intensity on the basis of normal scalp to the left (Sinclair et al., 2005).
Figure 5 Diagram

Sinclair's classification divides midline pattern alopecia into four intensity levels, progressing from a normal-appearing scalp to increasingly visible widening of the central part. The scale, introduced by Sinclair et al. (2005), provides a practical visual reference for clinicians assessing hair loss severity.

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.

Fig. 4. Olsen´s classification. Olsen patterns incorporate the accentuation of the front-overtical alopecia, which has a triangular or Christmas tree form with hair loss in a triangular form in the front-overtical area (Olsen, 2002).
Figure 6 Diagram

Olsen's classification system highlights the characteristic triangular or Christmas-tree pattern of frontovertical alopecia seen in female pattern hair loss. The accentuation of thinning at the frontal midline distinguishes this pattern from the more diffuse Ludwig classification.

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.

Fig. 5. Summary of evidence for the use of combination treatment of topical minoxidil in male and female androgenetic alopecia (Varothai and Bergfeld, 2014)
Figure 7

A summary of clinical evidence supporting combination therapy with topical minoxidil for androgenetic alopecia in both men and women. The data, compiled by Varothai and Bergfeld (2014), indicates that multi-modal treatment approaches may offer improved outcomes compared to monotherapy.

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.

Figure 2
Figure 2 Diagram

Classification systems for androgenetic alopecia severity are presented, distinguishing male and female pattern hair loss stages.

Androgenetic alopecia: An update.

Fig 3. Dihydrotestosterone (DHT) synthesis by SRD5A2 in AGA. The SRD5A2 synthesizes DHT by converting testosterone in the presence of NADPH to DHT.
Figure 3 Diagram

The DHT synthesis pathway via SRD5A2 is diagrammed, showing how 5-alpha reductase converts testosterone to dihydrotestosterone in the presence of NADPH, the key hormonal driver of AGA.

Androgenetic alopecia: An update.

Fig 4. Mechanism of inhibition by finasteride - covalent adduct between NADPH and finasteride. E57TM2 facilitates the hydride transfer to the D1,2 bond of finasteride to the covalent bond in the red circle. The covalent bond prevents a further hydride trans
Figure 4 Diagram

Finasteride's mechanism of inhibition is depicted at the molecular level, showing covalent adduct formation between NADPH and finasteride that prevents further hydride transfer to testosterone.

Androgenetic alopecia: An update.

Fig 5. The structure of human SRD5A2. (A), Spheres represent NADP-DHF adduct. L1-6 are the 6 loops connecting the 7 transmembranes (TM), and the TM portion has 254 amino acid residues. (B), The active site inside the 7 TM channels surrounded by L1, L3, an
Figure 5 Diagram

The three-dimensional structure of human SRD5A2 is shown with its seven transmembrane domains, active site, and NADP-DHF adduct positioning within the enzyme channel.

Androgenetic alopecia: An update.

Figure 5
Figure 5 Diagram

A proposed treatment algorithm for female pattern hair loss incorporates finasteride as a potential alternative when topical minoxidil fails, including appropriate patient selection criteria and monitoring requirements.

Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: …

Fig. 1 PRISMA flowchart. A PRISMA flowchart detailing the process of eligibility for all records reviewed for the literature review, as well as the number of studies identified, screened, excluded, and included
Figure 1 Flowchart

PRISMA flowchart detailing the systematic literature search and screening process for studies on microneedling in hair loss disorders. The diagram tracks records from initial identification through screening, eligibility assessment, and final inclusion.

Microneedling and Its Use in Hair Loss Disorders: A Systematic Review.

Figure 1. Flow chart diagram illustrating the database searches, number of publications identified, screened, and final full texts included in the systematic review.
Figure 2

Figure 1. Flow chart diagram illustrating the database searches, number of publications identified, screened, and final full texts included in the systematic review.

The Role of Minoxidil in Treatment of Alopecia Areata: A Systematic Review …

Figure 3
Figure 3

The Role of Minoxidil in Treatment of Alopecia Areata: A Systematic Review …

In total, 164 patients treated with less than 5% minoxidil were included in the metaanalysis. For the group of patients using minoxidil at a concentration lower than 5%, the response rate was 58% (95% Cl 0.5–0.67), and the prediction interval for the vari
Figure 4

In total, 164 patients treated with less than 5% minoxidil were included in the metaanalysis. For the group of patients using minoxidil at a concentration lower than 5%, the response …

The Role of Minoxidil in Treatment of Alopecia Areata: A Systematic Review …

Figure 5
Figure 5

The Role of Minoxidil in Treatment of Alopecia Areata: A Systematic Review …

Figure 3
Figure 3

Epidemiological landscape of androgenetic alopecia in the US: An All of Us …

Figure 4
Figure 4

Epidemiological landscape of androgenetic alopecia in the US: An All of Us …

Figure 5
Figure 5

Epidemiological landscape of androgenetic alopecia in the US: An All of Us …

Fig 4. Likelihood of AGA reporting for females by comorbid condition. All data is represented as odds ratios of the condition compared to control with corresponding p-value and interpretation.
Figure 6

Fig 4. Likelihood of AGA reporting for females by comorbid condition. All data is represented as odds ratios of the condition compared to control with corresponding p-value and interpretation.

Epidemiological landscape of androgenetic alopecia in the US: An All of Us …

Figure 1
Figure 1

Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.